<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02286973</url>
  </required_header>
  <id_info>
    <org_study_id>B-1407/257-005</org_study_id>
    <nct_id>NCT02286973</nct_id>
  </id_info>
  <brief_title>Combined Administration of Intravenous and Topical Tranexamic Acid in Total Knee Arthroplasty</brief_title>
  <official_title>Combined Administration of Intravenous and Topical Tranexamic Acid in Total Knee Arthroplasty: Is it the Most Effective Regime? A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <brief_summary>
    <textblock>
      This prospective randomized controlled trial was conducted To compare the efficacy of TNA in
      terms of total blood loss and the allogenic transfusion rate among the three study groups;
      intravenous alone, combined intravenous and low dose topical TNA and combined intravenous and
      high dose topical TNA.

      To evaluate the safety of each regimen in view of deep vein thrombosis and venous
      thromboembolism.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hemoglobin</measure>
    <time_frame>baseline and 5 days</time_frame>
    <description>Blood loss reduce</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Degenerative Arthritis</condition>
  <arm_group>
    <arm_group_label>Only Intravenous Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Only Intravenous Injection During Operation, 10mg/kr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous + Topical 1g Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous Injection During Operation, 10mg/kr
After Capsule Closure, Tranexamic acid Topical Injection 1g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous + Topical 2g Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous Injection During Operation, 10mg/kr
After Capsule Closure, Tranexamic acid Topical Injection 2g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Intravenous, Only Topical 2g Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Only Topical Injection 2g</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <arm_group_label>Only Intravenous Group</arm_group_label>
    <arm_group_label>Intravenous + Topical 1g Group</arm_group_label>
    <arm_group_label>Intravenous + Topical 2g Group</arm_group_label>
    <arm_group_label>No Intravenous, Only Topical 2g Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with diagnosis of primary osteoarthritis

        Exclusion Criteria:

          -  patients with diagnoses other than primary OA

          -  patients on anticoagulation therapy

          -  patient with chronic renal failure

          -  patient with CVA Hx

          -  Patient with seizure Hx

          -  Patient with severe CHF

          -  Patient with acquired or congenital coagulopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>TaeKyun Kim, MD,PhD</last_name>
    <phone>082-031-787-3355</phone>
    <email>osktk@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sungyup Lee, MD</last_name>
    <phone>082-031-787-6480</phone>
    <email>oslsy1204@gmail.com</email>
  </overall_contact_backup>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2014</study_first_submitted>
  <study_first_submitted_qc>November 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2014</study_first_posted>
  <last_update_submitted>November 7, 2014</last_update_submitted>
  <last_update_submitted_qc>November 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Tae Kyun Kim</investigator_full_name>
    <investigator_title>Director, Clinical Research</investigator_title>
  </responsible_party>
  <keyword>Tranexamic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

